Clinical Trials Logo
  1. Home
  2. Acute Graft Versus Host Disease
  3. NCT06026371

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Acute Graft Versus Host Disease Clinical Trial

Official title:
Fecal Microbiota Transplantation to Prevent Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Clinical Trial Summary

This randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation involves receiving processed fecal material orally after allogeneic HCT in order to establish a healthy gut microbiota. Gut microbiota undergoes major alterations during allogeneic HCT because of antibiotic exposures, nutritional changes, and chemotherapy administration. Establishing a healthy gut microbiota via fecal transplantation may help prevent acute graft versus host disease in patients undergoing allogeneic HCT.

Clinical Trial Description

OUTLINE: The first 12 patients are assigned to group I, remaining patients are randomized to 1 of 2 groups. GROUP I: Patients receive fecal microbiota capsules orally (PO) once daily (QD) for 7 days starting at the time of neutrophil engraftment and discontinuation of anti-bacterial antibiotics. GROUP II: Patients receive placebo PO QD for 7 days starting at the time of neutrophil engraftment and discontinuation of anti-bacterial antibiotics. After completion of study intervention, patients are followed up monthly until 12 months post-allogeneic HCT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06026371
Study type Interventional
Source Fred Hutchinson Cancer Center
Contact Armin Rashidi
Phone 206-667-2506
Email arashidi@fredhutch.org
Status Recruiting
Phase Phase 2
Start date December 12, 2023
Completion date September 30, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01140984 - Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD) N/A
Completed NCT00803010 - Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation Phase 2
Withdrawn NCT04280471 - Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease Phase 1
Withdrawn NCT02425813 - Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract Phase 2
Terminated NCT00038792 - Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD Phase 1/Phase 2
Terminated NCT04521777 - Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid Myopathy N/A
Terminated NCT02436460 - A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant Phase 1
Not yet recruiting NCT01596192 - PETCT for Diagnosing and Monitoring Acute GVHD N/A
Completed NCT00726375 - The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease Phase 3
Recruiting NCT05823675 - Safety and Clinical Activity of Itolizumab in aGVHD Phase 1
Not yet recruiting NCT06386445 - Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
Recruiting NCT05443425 - Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies Phase 1
Recruiting NCT03158896 - Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease Phase 1
Active, not recruiting NCT04976699 - CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Phase 3
Terminated NCT04095858 - Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Phase 3
Terminated NCT00032773 - Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD Phase 1/Phase 2
Completed NCT02359929 - BMT Autologous MSCs for GvHD Phase 1
Withdrawn NCT00640497 - Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease Phase 1/Phase 2
Completed NCT03491215 - Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease Phase 1/Phase 2
Completed NCT02687646 - Clinical Trial With MSC for Graft Versus Host Disease Treatment Phase 1/Phase 2